Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.

Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, König A, Fernandes O, Karlsson M, Helenius G, Karlsson C, Rahnenführer J, Hengstler JG, Micke P.

Clin Cancer Res. 2013 Jan 1;19(1):194-204. doi: 10.1158/1078-0432.CCR-12-1139. Epub 2012 Oct 2.

2.

Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.

Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH.

Am J Respir Crit Care Med. 2010 Jan 15;181(2):181-8. doi: 10.1164/rccm.200812-1807OC. Epub 2009 Oct 15.

PMID:
19833826
3.

Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.

Lu Y, Wang L, Liu P, Yang P, You M.

PLoS One. 2012;7(1):e30880. doi: 10.1371/journal.pone.0030880. Epub 2012 Jan 23.

4.

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.

Lung Cancer. 2009 Mar;63(3):410-7. doi: 10.1016/j.lungcan.2008.06.003. Epub 2008 Jul 11.

PMID:
18620780
5.

Methylation markers of early-stage non-small cell lung cancer.

Lokk K, Vooder T, Kolde R, Välk K, Võsa U, Roosipuu R, Milani L, Fischer K, Koltsina M, Urgard E, Annilo T, Metspalu A, Tõnisson N.

PLoS One. 2012;7(6):e39813. doi: 10.1371/journal.pone.0039813. Epub 2012 Jun 29.

6.

Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.

Masuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Clin Cancer Res. 2011 Dec 15;17(24):7712-22. doi: 10.1158/1078-0432.CCR-11-0619. Epub 2011 Oct 20.

7.

Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.

Wan YW, Beer DG, Guo NL.

Lung Cancer. 2012 Apr;76(1):98-105. doi: 10.1016/j.lungcan.2011.09.016. Epub 2011 Nov 1.

8.

Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.

Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W.

J Surg Oncol. 2011 Dec;104(7):847-51. doi: 10.1002/jso.22008. Epub 2011 Jun 30.

PMID:
21721011
9.

High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.

Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX.

Eur J Surg Oncol. 2012 Jun;38(6):523-30. doi: 10.1016/j.ejso.2012.02.180. Epub 2012 Mar 21.

PMID:
22440742
10.

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.

Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH, Zhang YK.

Med Oncol. 2012 Jun;29(2):618-26. doi: 10.1007/s12032-011-9923-y. Epub 2011 Apr 24.

PMID:
21516486
11.

Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens.

van den Berg RM, Snijders PJ, Grünberg K, Kooi C, Spreeuwenberg MD, Meijer CJ, Postmus PE, Smit EF, Steenbergen RD.

Lung Cancer. 2011 Jun;72(3):316-21. doi: 10.1016/j.lungcan.2010.10.005. Epub 2010 Nov 9.

12.

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

Clin Cancer Res. 2012 May 1;18(9):2695-703. doi: 10.1158/1078-0432.CCR-11-2210. Epub 2012 Feb 20.

13.

Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer.

Dango S, Sienel W, Schreiber M, Stremmel C, Kirschbaum A, Pantel K, Passlick B.

Lung Cancer. 2008 Jun;60(3):426-33. doi: 10.1016/j.lungcan.2007.11.015. Epub 2008 Jan 22.

PMID:
18215438
14.

An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.

Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N.

Clin Cancer Res. 2009 Jan 1;15(1):284-90. doi: 10.1158/1078-0432.CCR-08-1258.

15.

RANTES expression is a predictor of survival in stage I lung adenocarcinoma.

Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG.

Clin Cancer Res. 2002 Dec;8(12):3803-12.

16.

Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.

Leithner K, Wohlkoenig C, Stacher E, Lindenmann J, Hofmann NA, Gallé B, Guelly C, Quehenberger F, Stiegler P, Smolle-Jüttner FM, Philipsen S, Popper HH, Hrzenjak A, Olschewski A, Olschewski H.

BMC Cancer. 2014 Jan 25;14:40. doi: 10.1186/1471-2407-14-40.

17.

Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.

Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, Kim H, Lee HJ, Choi HY, Jung Y, Park M, Lim YS, Kim K, Shim Y, Kim BC, Lee K, Huh N, Ko C, Park K, Lee JW, Choi YS, Kim J.

Clin Cancer Res. 2008 Nov 15;14(22):7397-404. doi: 10.1158/1078-0432.CCR-07-4937.

18.

Gene expression-based classification of non-small cell lung carcinomas and survival prediction.

Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S.

PLoS One. 2010 Apr 22;5(4):e10312. doi: 10.1371/journal.pone.0010312.

19.

Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.

Võsa U, Vooder T, Kolde R, Fischer K, Välk K, Tõnisson N, Roosipuu R, Vilo J, Metspalu A, Annilo T.

Genes Chromosomes Cancer. 2011 Oct;50(10):812-22. doi: 10.1002/gcc.20902. Epub 2011 Jul 11.

PMID:
21748820
20.

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G.

Diagn Mol Pathol. 2003 Dec;12(4):201-11.

PMID:
14639106
Items per page

Supplemental Content

Write to the Help Desk